about
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.Primary leptomeningeal lymphoma: International Primary CNS Lymphoma Collaborative Group report.Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcomePotential role of preoperative conventional MRI including diffusion measurements in assessing epidermal growth factor receptor gene amplification status in patients with glioblastomaVinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial.Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.A prognostic gene expression signature in infratentorial ependymoma.Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Transcriptional diversity of long-term glioblastoma survivors.R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivoEfficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer.Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients.Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma.Clinical Reasoning: Worsening neurologic symptoms in a brain tumor patientSalvage temozolomide for prior temozolomide responders.Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification.Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidencePhase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumorsMethotrexate re-challenge for recurrent primary central nervous system lymphomaPrimary central nervous system lymphoma: is there still a role for radiotherapy?Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy.Complications of radiotherapy to the central nervous system.Atypical and anaplastic meningiomas treated with bevacizumab.Glioblastoma and other malignant gliomas: a clinical review.Current role of anti-angiogenic strategies for glioblastoma.Emerging therapies for glioblastoma.Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system.Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer.Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced-MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma.Diffusion-weighted MR imaging and MGMT methylation status in glioblastoma: a reappraisal of the role of preoperative quantitative ADC measurements.Continuing the search for MR imaging biomarkers for MGMT promoter methylation status: conventional and perfusion MRI revisited.What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas?High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib.EGFR tyrosine kinase domain mutations in human gliomas.A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases.Limited overall survival in patients with brain metastases from triple negative breast cancer.Chemotherapy-related magnetic resonance imaging abnormalities mimicking disease progression following intraventricular liposomal cytarabine and high dose methotrexate for neurolymphomatosis.Ventriculoperitoneal shunt in patients with leptomeningeal metastasis.
P50
Q30361848-C56DF9F1-0C2B-4BAE-9CA8-44F663DB2E48Q30409639-CF2B730E-9CCA-4907-B08F-A54EB45FD891Q30457046-5A161AB8-AEED-4D02-99ED-C10F905F7D3CQ30652283-665C9E88-34B6-4E25-A811-0BD04D9E6A97Q33370856-210E1A12-846D-4BC2-B279-BAC314E6AD64Q33423176-75B68ABC-8D2E-4F73-98CB-02DE886CF265Q33581494-6BCDD54F-C716-40A5-9F2E-BC86BC0C30DDQ33916064-A65F6FF4-14E8-4DB9-95F1-DBE5B71CC2ABQ34062027-62C6E3B7-DA64-4B4D-930A-1F3256FD9828Q35126247-5DA5BB93-F89C-415F-AA58-0BE251C22DB8Q35606075-61BB0FBC-5AA3-4A66-A70D-11AA661F2908Q35635056-4BEFF124-7752-4E0A-8CCB-C165AF989A17Q35788894-7E9D0D89-A805-4757-87C7-138C4F91C8FAQ35911026-8B9B491C-061D-44CC-81D3-3127AC40A83CQ35992951-846379B1-F179-492A-A67C-44A20AD49E6FQ36306363-BD57DF8F-DEF8-48C9-959E-D1A25325898FQ36459981-4A06DA52-B573-4684-816E-B37492621708Q36515232-C61458A6-E8EB-45F8-8DA8-9D70115BC59AQ36544101-3D858955-BEDC-4402-9934-98A3FD060DFFQ36870131-9AD5F19E-2EA5-48E1-89E0-9342D3C96082Q37600487-7F45E319-D272-4E6B-B65E-8EF4DC9176A9Q37941995-D2A784B3-5EEA-4A9F-8AA0-1910A9679739Q37956873-4242D25A-0DBC-41AC-8BF8-C5B599CA0505Q37974416-E2C5D3AF-D075-4ACF-B020-EC865B37211AQ38006444-8D33ABCF-E963-4DC4-B207-E405421F9D09Q38160159-8113B3D5-BF2A-43C6-9413-BCE67B710FB6Q38244844-55A7C169-DE15-439F-8914-882A43219D17Q38253154-67C66E2E-929B-46C0-827D-35B7CEDBB1AEQ39459076-FB6BE3A7-D527-4909-9A9A-AD6AD46AEB3AQ40308252-D9B4F203-CE50-4B08-A77F-81AEB9B5EE37Q40433973-D5A1B097-21ED-45FA-ACF3-2519365E5CACQ43071200-F4428EBB-C4F8-4C25-B38C-C4E9ED7F539AQ43071953-E693F869-026E-4D5F-866B-04237CF68D01Q46260819-572FA614-62E2-4F16-9F90-C23BE552CBAEQ46448637-9E770EF2-B7A4-4F65-BB40-ECB5A72CF9FDQ46455469-4C8D7C50-FE4E-4AF8-A9E1-001585CC305FQ46911568-37876B72-5D8E-47FA-9209-9428CE4D136FQ48505232-F6D00A0E-1765-493D-BE49-37B995987542Q48714811-851263DA-ED0D-4909-9558-2489BA1F36BAQ48893651-FA7CE113-1BCB-44F3-BD94-9B2311437B6B
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Antonio Omuro
@ast
Antonio Omuro
@en
Antonio Omuro
@es
Antonio Omuro
@nl
Antonio Omuro
@sl
type
label
Antonio Omuro
@ast
Antonio Omuro
@en
Antonio Omuro
@es
Antonio Omuro
@nl
Antonio Omuro
@sl
altLabel
Antonio M Omuro
@en
prefLabel
Antonio Omuro
@ast
Antonio Omuro
@en
Antonio Omuro
@es
Antonio Omuro
@nl
Antonio Omuro
@sl
P106
P108
P21
P31
P496
0000-0003-4299-3664